ClinicalTrials.gg
Not yet recruitingNCT07948278HPV VaccineUpdated Nov 19, 2026

15-Year Follow-up of Protection and Immunity After Bivalent HPV Vaccination in Women

An observational study in Cervical Intraepithelial Neoplasia and Persistent Infection, sponsored by Xiamen University. Not yet recruiting at 3 sites in China. Open to female participants, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-19.

Sponsored by Xiamen University · Observational

How we know

Updated Nov 19, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
2,000
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-20

Among 56 studies in Uterine Cervical Dysplasia with a site in China — 11 open to participants now, 15 under way, 1 of them phase 3. Uterine Cervical Dysplasia · China.

Planned enrollment
10th of 22
2,000 · median 1,270
Started
2027
the only one that year
Observational
22 of 56
5 open now
Primary completion
2029-12
later than 14 of 14 live
Registered
56th of 56
by date
Lead sponsor
5 of 56
Xiamen University

Among the 56 studies in Uterine Cervical Dysplasia with a site in China, this one is the 10th largest by planned enrollment of the 22 observational ones that give a count, is the only one that started in 2027, is one of 22 observational ones, reaches primary completion later than 14 of the 14 other live ones, and was the 56th registered.

Uterine Cervical Dysplasia

410 studies on the registry are indexed under Uterine Cervical Dysplasia; 76 are open to participants now.

Browse Uterine Cervical Dysplasia studies →

Open to participants now

11 of the 56 studies in Uterine Cervical Dysplasia with a site in China are open now. Recruiting first, the newest first:

5 more — sign in →

All 11 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 43 Uterine Cervical Dysplasia studies recruiting now, 19 (44%) set no upper age limit and 21 (49%) stop at 75 or younger; 3 take children under 18; 11 take healthy volunteers.

This study: female · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 56 studies in Uterine Cervical Dysplasia with a site in China, or all of them as a file.
02

Study summary

This study aims to evaluate the long-term protection provided by a bivalent HPV vaccine produced in Escherichia coli against specific clinical endpoints related to HPV types 16 and 18 in women aged 18-45 years, as well as the persistence of antibodies specific to these two HPV types.

Read the detailed description

This observational study is a long-term follow-up of participants in the phase III clinical trial of a bivalent HPV 16/18 vaccine produced in Escherichia coli (HPV-PRO-003, NCT01735006). Women aged 18-45 years at enrollment in the original trial were randomly assigned to receive either the HPV vaccine or a hepatitis E vaccine. The follow-up study will retain the original vaccine and control groups. No additional study intervention will be administered.

Through 15 years after the first dose, this study aims to evaluate the long-term protection provided by the bivalent HPV vaccine against specific clinical endpoints associated with HPV types 16 and/or 18 and to assess the persistence of antibodies specific to HPV types 16 and 18.

03

Conditions studied

  • Cervical Intraepithelial Neoplasia
  • Persistent Infection

Keywords

  • Human Papilloma Virus 16
  • Human Papilloma Virus 18
  • Long-term Effectiveness
  • Immuno-persistence
04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
Female
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

The study population comprises women who received at least one dose of their assigned vaccine in the original phase III trial of the Escherichia coli-produced recombinant bivalent vaccine against human papillomavirus (HPV) types 16 and 18 (protocol HPV-PRO-003). To be eligible, women must not have received any HPV vaccine outside their original trial assignment since enrollment in that trial, including any subsequent catch-up doses given to control group participants. Participants retain their original group assignments (HPV vaccine group or hepatitis E vaccine control group).

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • The participant took part in the phase III trial of the Escherichia coli-produced recombinant bivalent vaccine against human papillomavirus (HPV) types 16 and 18 (protocol HPV-PRO-003) and received at least one dose of the vaccine assigned to her in that trial.
  • The participant has given and signed the consent form.
  • The participant is able to complete all study procedures as required by the protocol.

Exclusion criteria

Exclusion Criteria:

  • Since enrollment in the original phase III trial, the participant has received any HPV vaccine other than the study vaccination assigned under the original trial protocol. This includes subsequent catch-up vaccination with the vaccine among participants in the original control group, as well as receipt of any other licensed or unlicensed HPV vaccine.
  • The participant had an invasive of the cervix, vagina, or vulva before enrollment in this follow-up study, or an abnormality detected at screening is confirmed to be an invasive malignancy at one of these sites by histopathological examination of a colposcopy-directed specimen.
  • In the investigator's judgment, a medical, psychological, social, occupational, or other circumstance would interfere with the participant's ability to comply with the protocol or to provide written .
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
2,000 participants (estimated)
Patient registry
No

Groups and cohorts

  • Vaccine group

    Women assigned to the vaccine group in the original phase III trial who received at least one dose of the bivalent HPV 16/18 vaccine. Since enrollment in the original trial, they must not have received any HPV vaccine other than the study vaccine administered as specified in that trial's protocol. Participants must also meet all other eligibility criteria for this follow-up study.

    Biological: Recombinant Human Papillomavirus Bivalent (Types 16, 18) Vaccine (Escherichia coli)

  • Control group

    Women assigned to the control group in the original phase III trial who received at least one dose of control vaccine (hepatitis E vaccine). Since enrollment in the original trial, they must not have received any HPV vaccine other than vaccination specified in the original trial protocol. Participants must also meet all other eligibility criteria for this follow-up study.

Interventions

  • BiologicalRecombinant Human Papillomavirus Bivalent (Types 16, 18) Vaccine (Escherichia coli)

    The bivalent HPV-16/18 vaccine was a mixture of two aluminum hydroxide adjuvant-absorbed recombinant L1 VLPs of HPV-16 and HPV-18 expressed in E. coli. A 0.5 ml dose of the bivalent HPV test vaccine comprised 40 μg of HPV-16 and 20 μg of HPV-18 L1 VLPs absorbed with 208 μg of aluminum adjuvant

06

What researchers measure

Primary outcomes

  1. CIN2+, VIN2+, or VaIN2+ associated with HPV type 16 or 18 in the per-protocol population

    This endpoint includes grade 2 or worse cervical, vulvar, or vaginal intraepithelial neoplasia associated with either or both HPV types

    Time frame: At months 156 and 180 after the first dose in the original trial

  2. 6-month persistent infection with HPV type 16 or 18 in the per-protocol population

    Infection with the same HPV type must persist for at least 6 months

    Time frame: At months 156 and 180 after the first dose in the original trial

Secondary outcomes

  1. CIN1+, VIN1+, or VaIN1+ associated with HPV type 16 or 18

    This endpoint includes grade 1 or worse cervical, vulvar, or vaginal intraepithelial neoplasia associated with either or both HPV types

    Time frame: At months 156 and 180 after the first dose in the original trial

  2. CIN2+ associated with HPV type 16 or 18

    This endpoint includes grade 2 or worse cervical intraepithelial neoplasia associated with either or both HPV types

    Time frame: At months 156 and 180 after the first dose in the original trial

  3. VIN2+, or VaIN2+ associated with HPV type 16 or 18

    This endpoint includes grade 2 or worse vulvar, or vaginal intraepithelial neoplasia associated with either or both HPV types

    Time frame: At months 156 and 180 after the first dose in the original trial

  4. HPV-16-specific infection and/or lesion endpoints

    6-month persistent infection and grade 2 or worse cervical intraepithelial

    Time frame: At months 156 and 180 after the first dose in the original trial

  5. HPV-18-specific infection and/or lesion endpoints

    6-month persistent infection and grade 2 or worse cervical intraepithelial

    Time frame: At months 156 and 180 after the first dose in the original trial

  6. Type-specific infection and/or lesion endpoints associated with other high-risk HPV types, including HPV-31, 33, 35, 39, 45, 51, 52, 56, 58, 59, and 68

    6-month persistent infection and grade 2 or worse cervical intraepithelial

    Time frame: At months 156 and 180 after the first dose in the original trial

  7. Type-specific seropositivity rates for HPV-16 and HPV-18 antibodies

    Percentage of participants seropositive for HPV-16 and HPV-18 antibodies

    Time frame: At months 156 and 180 after the first dose in the original trial

  8. Type-specific HPV-16 and HPV-18 antibody levels

    Serum antibody titers against HPV-16 and HPV-18

    Time frame: At months 156 and 180 after the first dose in the original trial

Other outcomes

  1. incident HPV-16 and/or HPV-18 infection

    Newly detected HPV-16 and/or HPV-18 DNA positivity

    Time frame: At months 156 and 180 after the first dose in the original trial

07

Study locations

3 sites
  • Liuzhou Center for Disease Control and Prevention
    Liuzhou, Guangxi 545007, China
  • Fengning Hospital of Traditional Chinese Medicine
    Fengning, Hebei 068350, China
  • Xinmi Maternal and Child Health Hospital
    Qingpingjie, Henan 452370, China
08

References and documents

Publications

  • Zhao F, Chen Q, Zhao C, Nie L, Hu S, Yin J, Qiu L, Bi Z, Quan J, Li Y, Li M, Zhang X, Pan Q, Li C, Ke L, Liu X, Zheng F, Dai C, Wang Z, Kuang X, Jia X, Su Y, Huang S, Zhang Q, Huang W, Wei L, Zhang J, Wu T, Qiao Y, Xia N. Long-term efficacy and immunopersistence of an Escherichia coli-produced HPV-16/18 bivalent vaccine: an observational extension study following a randomised, double-blind Phase III clinical trial cohort. Lancet Reg Health West Pac. 2025 Aug 21;61:101668. doi: 10.1016/j.lanwpc.2025.101668. eCollection 2025 Aug. PubMed 40893604 ↗
  • Zhao FH, Wu T, Hu YM, Wei LH, Li MQ, Huang WJ, Chen W, Huang SJ, Pan QJ, Zhang X, Hong Y, Zhao C, Li Q, Chu K, Jiang YF, Li MZ, Tang J, Li CH, Guo DP, Ke LD, Wu X, Yao XM, Nie JH, Lin BZ, Zhao YQ, Guo M, Zhao J, Zheng FZ, Xu XQ, Su YY, Zhang QF, Sun G, Zhu FC, Li SW, Li YM, Pan HR, Zhang J, Qiao YL, Xia NS. Efficacy, safety, and immunogenicity of an Escherichia coli-produced Human Papillomavirus (16 and 18) L1 virus-like-particle vaccine: end-of-study analysis of a phase 3, double-blind, randomised, controlled trial. Lancet Infect Dis. 2022 Dec;22(12):1756-1768. doi: 10.1016/S1473-3099(22)00435-2. Epub 2022 Aug 26. PubMed 36037823 ↗
  • Qiao YL, Wu T, Li RC, Hu YM, Wei LH, Li CG, Chen W, Huang SJ, Zhao FH, Li MQ, Pan QJ, Zhang X, Li Q, Hong Y, Zhao C, Zhang WH, Li YP, Chu K, Li M, Jiang YF, Li J, Zhao H, Lin ZJ, Cui XL, Liu WY, Li CH, Guo DP, Ke LD, Wu X, Tang J, Gao GQ, Li BY, Zhao B, Zheng FX, Dai CH, Guo M, Zhao J, Su YY, Wang JZ, Zhu FC, Li SW, Pan HR, Li YM, Zhang J, Xia NS. Efficacy, Safety, and Immunogenicity of an Escherichia coli-Produced Bivalent Human Papillomavirus Vaccine: An Interim Analysis of a Randomized Clinical Trial. J Natl Cancer Inst. 2020 Feb 1;112(2):145-153. doi: 10.1093/jnci/djz074. PubMed 31086947 ↗

Individual participant data

Plan to share: Undecided — Proposals should be sent to the Principal Investigator. Proposals will be reviewed and approved by the study team.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jan 2027; primary completion for Dec 2029, 35 months later.

Of 44 observational studies under Uterine Cervical Dysplasia, half reached primary completion within 61 months of starting (the median), counting those still running; a quarter within 30. This study's planned 35 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 14, 2026
First posted
Nov 19, 2026
StartEst.
Jan 1, 2027
Primary completionEst.
Dec 31, 2029
CompletionEst.
Dec 31, 2029
Last update
Nov 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 19, 2026
Show all 1 update
  1. Nov 19, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07948278
Lead sponsor
Xiamen University
Responsible party
Jun Zhang (professor, Xiamen University) — Principal investigator
First posted
Nov 19, 2026
Start date
Jan 1, 2027 (estimated)
Primary completion
Dec 31, 2029 (estimated)
Completion
Dec 31, 2029 (estimated)
Last update
Nov 19, 2026

Study contacts

Ting Wu
Contact
wuting.@xmu.edu.cn
0592-2880621
Ting Wu
principal investigator · Xiamen University
Jun Zhang
study chair · Xiamen University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion